Treatment Details – 6.0 months

Survival: 6.0 months
  
Toxicity Grade:4
  
Treatments: Chemotherapy
  
Drugs: Ranpirnase
Country:United States
  
City/State/Province:Bloomfield, New Jersey
  
Hospital:Alfacell Corp.
  
Journal:Link
  
Date: 1/2002

Description:
Patients: This Phase II study involved 105 patients with unresectable malignant mesothelioma.

Treatment: The treatment consisted of administration of the drug ranpirnase (onconase).

Toxicity: There were ten deaths during the study and eleven deaths within 30 days of the last dose of treatment. The authors, however, concluded, that there no serious adverse events or deaths related to ranpirnase treatment. Grade 3 or 4 toxicities included hypotension, anaphylactoid reaction, worsening of lupus symptoms, kidney function abnormalities, asthenia, edema, arthralgia, pain, anorexia, nausea, myalgia, flu syndrome, and neuropathy.

Results: The overall median survival time was 6 months.

Support: The study was supported by Alfacell Corporation and two of the study’s authors work for Alfacell. Alfacell markets ranpirnase.

Correspondence: Stanislaw Mikulski

Get your free copy of
“Surviving Mesothelioma” Today!